Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer - Concepedia

Concepedia

Publication | Open Access

Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer

DOI Full Paper Access

119

Citations

24

References

2008

Year

Yuichiro Ohe, Yukito Ichinose, Kazuhiko Nakagawa, Tomohide Tamura, Kaoru Kubota, Nobuyuki Yamamoto, Susumu Adachi, Yoshihiro Nambu, Toshio Fujimoto, Yutaka Nishiwaki,

Clinical Cancer Research

Abstract

P500 and P1000 are similarly active with promising efficacy and acceptable safety outcomes in pretreated patients with NSCLC. These results support the use of P500 as a second- and third-line treatment of NSCLC.

References

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Journal of Clinical Oncology	2003	3K
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, Journal of Clinical Oncology	2004	2.4K
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Frances A. Shepherd, Janet Dancey, Rodryg Ramlau, Journal of Clinical Oncology	2000	2.2K
Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. Marianne J. Brady, David Cella, Fei Mo, Journal of Clinical Oncology	1997	1.7K
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument David Cella, Amy E. Bonomi, Stephen Lloyd, Lung Cancer Quality Of LifeLife AssessmentCancer ManagementFunctional AssessmentOncology	1995	742
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan Yuichiro Ohe, Yasuo Ohashi, Kaoru Kubota, Annals of Oncology	2006	635
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Paolo Ceppi, Marco Volante, Silvia Saviozzi, Cancer	2006	363
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B<sub>12</sub> as Front-Line Therapy in Malignant Pleural Mesothelioma Giorgio V. Scagliotti, Dong-M. Shin, Hedy L. Kindler, Journal of Clinical Oncology	2003	255
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Clet Niyikiza, Sharyn D. Baker, David E. Seitz, PubMed Drug SafetyPretreatment Methylmalonic AcidTherapeutic Drug MonitoringOncologyPemetrexed Therapy	2002	247

Page 1